Annual Total Liabilities
$2.41 B
-$338.18 M-12.33%
December 31, 2023
Summary
- As of February 22, 2025, SRPT annual total liabilities is $2.41 billion, with the most recent change of -$338.18 million (-12.33%) on December 31, 2023.
- During the last 3 years, SRPT annual total liabilities has risen by +$182.28 million (+8.20%).
- SRPT annual total liabilities is now -12.33% below its all-time high of $2.74 billion, reached on December 31, 2022.
Performance
SRPT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$2.38 B
+$31.68 M+1.35%
September 30, 2024
Summary
- As of February 22, 2025, SRPT quarterly total liabilities is $2.38 billion, with the most recent change of +$31.68 million (+1.35%) on September 30, 2024.
- Over the past year, SRPT quarterly total liabilities has dropped by -$26.38 million (-1.10%).
- SRPT quarterly total liabilities is now -13.29% below its all-time high of $2.74 billion, reached on December 31, 2022.
Performance
SRPT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
SRPT Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.3% | -1.1% |
| 3 y3 years | +8.2% | -12.7% |
| 5 y5 years | +294.4% | -12.7% |
SRPT Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -12.3% | +8.3% | -13.3% | +8.2% |
| 5 y | 5-year | -12.3% | +139.4% | -13.3% | +136.8% |
| alltime | all time | -12.3% | >+9999.0% | -13.3% | >+9999.0% |
Sarepta Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.38 B(+1.3%) |
| Jun 2024 | - | $2.35 B(+3.7%) |
| Mar 2024 | - | $2.26 B(-5.9%) |
| Dec 2023 | $2.41 B(-12.3%) | $2.41 B(+2.6%) |
| Sep 2023 | - | $2.35 B(-1.6%) |
| Jun 2023 | - | $2.38 B(+1.6%) |
| Mar 2023 | - | $2.35 B(-14.4%) |
| Dec 2022 | $2.74 B(+23.6%) | $2.74 B(+0.7%) |
| Sep 2022 | - | $2.73 B(+20.0%) |
| Jun 2022 | - | $2.27 B(+3.2%) |
| Mar 2022 | - | $2.20 B(-0.9%) |
| Dec 2021 | $2.22 B(-0.1%) | $2.22 B(+1.2%) |
| Sep 2021 | - | $2.19 B(-3.6%) |
| Jun 2021 | - | $2.27 B(+2.0%) |
| Mar 2021 | - | $2.23 B(+0.3%) |
| Dec 2020 | $2.22 B(+121.3%) | $2.22 B(+17.7%) |
| Sep 2020 | - | $1.89 B(+2.6%) |
| Jun 2020 | - | $1.84 B(+2.1%) |
| Mar 2020 | - | $1.80 B(+79.4%) |
| Dec 2019 | $1.00 B(+64.7%) | $1.00 B(+42.0%) |
| Sep 2019 | - | $707.27 M(+9.0%) |
| Jun 2019 | - | $648.59 M(+5.4%) |
| Mar 2019 | - | $615.33 M(+0.9%) |
| Dec 2018 | $609.80 M(+17.6%) | $609.80 M(+12.3%) |
| Sep 2018 | - | $543.06 M(-0.9%) |
| Jun 2018 | - | $548.11 M(+4.7%) |
| Mar 2018 | - | $523.52 M(+0.9%) |
| Dec 2017 | $518.75 M(+493.4%) | $518.75 M(+403.0%) |
| Sep 2017 | - | $103.13 M(+42.5%) |
| Jun 2017 | - | $72.37 M(-12.2%) |
| Mar 2017 | - | $82.39 M(-5.7%) |
| Dec 2016 | $87.41 M(+4.8%) | $87.41 M(+11.1%) |
| Sep 2016 | - | $78.69 M(-4.7%) |
| Jun 2016 | - | $82.61 M(+11.0%) |
| Mar 2016 | - | $74.40 M(-10.8%) |
| Dec 2015 | $83.44 M(+76.1%) | $83.44 M(+35.6%) |
| Sep 2015 | - | $61.52 M(-7.3%) |
| Jun 2015 | - | $66.33 M(+58.1%) |
| Mar 2015 | - | $41.95 M(-11.5%) |
| Dec 2014 | $47.38 M(+6.8%) | $47.38 M(+44.2%) |
| Sep 2014 | - | $32.85 M(-12.1%) |
| Jun 2014 | - | $37.39 M(-19.5%) |
| Mar 2014 | - | $46.43 M(+4.6%) |
| Dec 2013 | $44.38 M(-45.4%) | $44.38 M(-22.8%) |
| Sep 2013 | - | $57.49 M(-39.4%) |
| Jun 2013 | - | $94.81 M(-10.6%) |
| Mar 2013 | - | $106.06 M(+30.4%) |
| Dec 2012 | $81.31 M(+248.2%) | $81.31 M(+41.1%) |
| Sep 2012 | - | $57.65 M(+194.1%) |
| Jun 2012 | - | $19.60 M(-39.9%) |
| Mar 2012 | - | $32.63 M(+39.7%) |
| Dec 2011 | $23.35 M(-52.1%) | $23.35 M(-20.4%) |
| Sep 2011 | - | $29.33 M(-26.3%) |
| Jun 2011 | - | $39.78 M(-13.7%) |
| Mar 2011 | - | $46.11 M(-5.5%) |
| Dec 2010 | $48.79 M | $48.79 M(+4.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2010 | - | $46.70 M(+16.1%) |
| Jun 2010 | - | $40.23 M(+37.0%) |
| Mar 2010 | - | $29.35 M(-19.4%) |
| Dec 2009 | $36.40 M(+271.2%) | $36.40 M(-20.2%) |
| Sep 2009 | - | $45.62 M(+58.2%) |
| Jun 2009 | - | $28.83 M(+104.1%) |
| Mar 2009 | - | $14.13 M(+44.1%) |
| Dec 2008 | $9.80 M(-20.0%) | $9.80 M(-25.6%) |
| Sep 2008 | - | $13.18 M(+16.2%) |
| Jun 2008 | - | $11.34 M(-22.9%) |
| Mar 2008 | - | $14.69 M(+19.9%) |
| Dec 2007 | $12.26 M(+289.0%) | $12.26 M(+5.3%) |
| Sep 2007 | - | $11.64 M(+66.4%) |
| Jun 2007 | - | $6.99 M(+60.9%) |
| Mar 2007 | - | $4.35 M(+38.0%) |
| Dec 2006 | $3.15 M(+14.7%) | $3.15 M(+44.3%) |
| Sep 2006 | - | $2.18 M(-3.6%) |
| Jun 2006 | - | $2.26 M(+2.5%) |
| Mar 2006 | - | $2.21 M(-19.6%) |
| Dec 2005 | $2.75 M(+22.2%) | $2.75 M(+8.9%) |
| Sep 2005 | - | $2.52 M(+30.9%) |
| Jun 2005 | - | $1.93 M(-15.4%) |
| Mar 2005 | - | $2.28 M(+1.3%) |
| Dec 2004 | $2.25 M(-40.0%) | $2.25 M(+66.7%) |
| Sep 2004 | - | $1.35 M(-37.7%) |
| Jun 2004 | - | $2.17 M(-21.2%) |
| Mar 2004 | - | $2.75 M(-26.7%) |
| Dec 2003 | $3.75 M(-26.8%) | $3.75 M(+62.5%) |
| Sep 2003 | - | $2.31 M(+78.1%) |
| Jun 2003 | - | $1.30 M(-20.0%) |
| Mar 2003 | - | $1.62 M(-68.4%) |
| Dec 2002 | $5.12 M(+56.1%) | $5.12 M(+4.2%) |
| Sep 2002 | - | $4.92 M(+24.3%) |
| Jun 2002 | - | $3.96 M(-16.2%) |
| Mar 2002 | - | $4.72 M(+43.9%) |
| Dec 2001 | $3.28 M(+90.5%) | $3.28 M(+107.5%) |
| Sep 2001 | - | $1.58 M(-2.0%) |
| Jun 2001 | - | $1.61 M(-0.2%) |
| Mar 2001 | - | $1.62 M(-6.1%) |
| Dec 2000 | $1.72 M(+72.3%) | $1.72 M(+30.9%) |
| Sep 2000 | - | $1.32 M(+19.2%) |
| Jun 2000 | - | $1.10 M(+44.0%) |
| Mar 2000 | - | $767.00 K(-23.3%) |
| Dec 1999 | $1.00 M(-16.7%) | $1.00 M(+42.9%) |
| Sep 1999 | - | $700.00 K(+75.0%) |
| Jun 1999 | - | $400.00 K(-42.9%) |
| Mar 1999 | - | $700.00 K(-41.7%) |
| Dec 1998 | $1.20 M(+140.0%) | $1.20 M(0.0%) |
| Sep 1998 | - | $1.20 M(+200.0%) |
| Jun 1998 | - | $400.00 K(-20.0%) |
| Mar 1998 | - | $500.00 K(0.0%) |
| Dec 1997 | $500.00 K(+66.7%) | $500.00 K(-37.5%) |
| Sep 1997 | - | $800.00 K(-11.1%) |
| Jun 1997 | - | $900.00 K(-74.3%) |
| Mar 1997 | - | $3.50 M |
| Dec 1996 | $300.00 K | - |
FAQ
- What is Sarepta Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual total liabilities year-on-year change?
- What is Sarepta Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly total liabilities year-on-year change?
What is Sarepta Therapeutics annual total liabilities?
The current annual total liabilities of SRPT is $2.41 B
What is the all time high annual total liabilities for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual total liabilities is $2.74 B
What is Sarepta Therapeutics annual total liabilities year-on-year change?
Over the past year, SRPT annual total liabilities has changed by -$338.18 M (-12.33%)
What is Sarepta Therapeutics quarterly total liabilities?
The current quarterly total liabilities of SRPT is $2.38 B
What is the all time high quarterly total liabilities for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly total liabilities is $2.74 B
What is Sarepta Therapeutics quarterly total liabilities year-on-year change?
Over the past year, SRPT quarterly total liabilities has changed by -$26.38 M (-1.10%)